Please login to the form below

Not currently logged in
Email:
Password:

Otezla

This page shows the latest Otezla news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts IO presence with Immatics deal

Celgene boosts IO presence with Immatics deal

The deal comes just days after the company confirmed the sale of its blockbuster psoriasis drug, Otezla to Amgen for $13.4bn, required by the US anti-trust regulator the FTC

Latest news

  • Amgen snaps up Celgene’s Otezla for $13.4bn Amgen snaps up Celgene’s Otezla for $13.4bn

    Amgen is confident that the portfolio fit, plus scope for further licence extensions, makes Otezla a good buy. ... BMS says that it will use the Otezla cash to pay off its debts faster, and to increase a planned post-merger share re-purchase from $5bn to

  • BMS buoyed by FDA approval of Celgene’s myelofibrosis drug BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

    regimen – as a second-line treatment for lymphoma, and a green light for Otezla (apremilast) for Behcet's disease. ... Otezla has to be offloaded by BMS and Celgene to get their merger through antitrust approval, but the new approval increases the

  • Triplet approvals for myeloma boost Celgene in Q2 Triplet approvals for myeloma boost Celgene in Q2

    Otezla buoyant. Meanwhile, Celgene’s other big product – Otezla (apremilast) for psoriasis, psoriatic arthritis and latterly Behçet’s disease – had another spectacular quarter with a 31% gain to $493m, just as

  • Opdivo trial overshadows BMS financial results Opdivo trial overshadows BMS financial results

    On BMS’ results call, Caforio said that “significant interest” had been received from potential buyers of Otezla (apremilast), a psoriasis therapy that has to be divested to get the deal through

  • Otezla scores new indication as speculation over potential buyers grows Otezla scores new indication as speculation over potential buyers grows

    The FTC pointed to Otezla and a BMS pipeline candidate in the therapy area, a tyrosine kinase 2 (TYK2) inhibitor, as the reason for these concerns. ... Analysts put a value of $5-10bn on Otezla, with its specific sale price dependant on the company that

More from news
Approximately 9 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Elsewhere, Celgene has seen large growth in 2017 (46%) - driven by sales of Otezla, the first oral small molecule to be approved for psoriasis and psoriatic arthritis.

  • Building a business that is lean and specialised Building a business that is lean and specialised

    This has been in the pipeline for some time and will face its first major sales and marketing test in Europe with the anticipated launch next year of Otezla (apremilast) for

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Infographic: RA Perceptions

    The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics